Follow-up Observational Study of the Randomised Intergroup Trial of First Line Treatment for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma With CHOP-Like Chemotherapy Regimen With or Without the Anti-CD20 Antibody Rituximab (IDEC-C2B8) [MINT]
- Gain information on the long-term efficacy of 6 courses of CHOP (cyclophosphamide,
doxorubicin hydrochloride, prednisone, and vincristine)-like chemotherapy with vs
without rituximab (plus involved-field radiotherapy to primary bulky disease) in young
patients with good-prognosis diffuse large B-cell non-Hodgkin's lymphoma treated on
- Gain information on late toxicities, including secondary neoplasm occurring in young
good-prognosis patients treated on protocol CAN-NCIC-LY9.
OUTLINE: This is a multicenter study.
Patients successfully completing treatment on protocol CAN-NCIC-LY9 are followed every 3
months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 667 patients will be accrued for this study.
Time to treatment failure
Michael G.M. Pfreundschuh, MD
Universitaetsklinikum des Saarlandes
United States: Federal Government